Inflammatory mechanisms in major depressive disorder

Current Opinion in Psychiatry

Volumn 24, Issue 6, 2011, Pages 519-525

  Raedler, Thomas J ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANTIDEPRESSANT AGENT; CANDESARTAN; CELECOXIB; CITALOPRAM; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; DEXAMETHASONE; DOCOSAHEXAENOIC ACID; ETANERCEPT; GAMMA INTERFERON; HYDROCORTISONE; IBUPROFEN; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; QUINOLINIC ACID; REBOXETINE; SEROTONIN TRANSPORTER; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA;

CADAVER; CEREBROSPINAL FLUID; CHRONIC STRESS; HEREDITY; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; MAJOR DEPRESSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PSORIASIS; PSYCHOSOMATIC DISORDER; REMISSION; REVIEW; SYMPTOM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIDEPRESSIVE AGENTS; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; HUMANS; INFLAMMATION;

EID: 80053385511     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0b013e32834b9db6     Document Type: Review

References (71)

1. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008; 358:55-68.
2. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289:3095-3105. (Pubitemid 37432885)
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3:e442.
4. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. 1965. J Neuropsychiatry Clin Neurosci 1995; 7:524-533.
5. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR-D report. Am J Psychiatry 2006; 163:1905-1917. (Pubitemid 44807782)
6. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354:1243-1252.
7. Dean B. Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. Int J Neuropsychopharmacol 2011; 14:997-1012.
8. Muller N, Myint AM, Schwarz MJ. Inflammatory biomarkers and depression. Neurotox Res 2011; 19:308-318.
9. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009; 65:732-741.
10. Raison CL, Lowry CA, Rook GA. Inflammation, sanitation, and consternation: loss of contact with coevolved, tolerogenic microorganisms and the pathophysiology and treatment of major depression. Arch Gen Psychiatry 2010; 67:1211-1224.
11. McEwen BS. Protective and damaging effects of stress mediators. N Engl J Med 1998; 338:171-179.
12. Cohen S, Janicki-Deverts D, Miller GE. Psychological stress and disease. JAMA 2007; 298:1685-1687. (Pubitemid 47606658)
13. Hasler G, Drevets WC, Manji HK, Charney DS. Discovering endophenotypes for major depression. Neuropsychopharmacology 2004; 29:1765-1781. (Pubitemid 39336788)
14. Ising M, Horstmann S, Kloiber S, et al. Combined dexamethasone/ corticotropin releasing hormone test predicts treatment response in major depression: a potential biomarker? Biol Psychiatry 2007; 62:47-54. (Pubitemid 46898222)
15. Steptoe A, Hamer M, Chida Y. The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain Behav Immun 2007; 21:901-912. (Pubitemid 47285684)
16. Kiecolt-Glaser JK, Preacher KJ, MacCallum RC, et al. Chronic stress and agerelated increases in the proinflammatory cytokine IL-6. Proc Natl Acad Sci U S A 2003; 100:9090-9095. (Pubitemid 36899228)
17. Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001; 49:391-404. (Pubitemid 32234301)
18. Pace TW, Miller AH. Cytokines and glucocorticoid receptor signaling: relevance to major depression. Ann N Y Acad Sci 2009; 1179:86-105.
19. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67:446-457.
20. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009; 71:171-186.
21. Ford DE, Erlinger TP. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2004; 164:1010-1014. (Pubitemid 38581522)
22. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000; 22:370-379. (Pubitemid 30105765)
23. Cizza G,Marques AH, Eskandari F, et al. Elevated neuroimmune biomarkers in sweat patches and plasma of premenopausal women with major depressive disorder in remission: the POWER study. Biol Psychiatry 2008; 64:907-911.
24. Janelidze S, Mattei D, Westrin A, et al. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain Behav Immun 2011; 25:335-339.
25. De BD, Conti CM, Serroni N, et al. The effect of newer serotonin-noradrenalin antidepressants on cytokine production: a review of the current literature. Int J Immunopathol Pharmacol 2010; 23:417-422.
26. Janssen DG, Caniato RN, Verster JC, Baune BT. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol 2010; 25:201-215.
27. Gimeno D, Kivimaki M, Brunner EJ, et al. Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol Med 2009; 39:413-423.
28. Milaneschi Y, Corsi AM, Penninx BW, et al. Interleukin-1 receptor antagonist and incident depressive symptoms over 6 years in older persons: the InCHIANTI study. Biol Psychiatry 2009; 65:973-978.
29. Pasco JA, Nicholson GC, Williams LJ, et al. Association of high-sensitivity C-reactive protein with de novo major depression. Br J Psychiatry 2010; 197:372-377.
30. Anisman H, Merali Z, Hayley S. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. Prog Neurobiol 2008; 85:1-74.
31. Glaser R, Robles TF, Sheridan J, et al. Mild depressive symptoms are associated with amplified and prolonged inflammatory responses after influenza virus vaccination in older adults. Arch Gen Psychiatry 2003; 60:1009-1014. (Pubitemid 37222084)
32. Slavich GM, Way BM, Eisenberger NI, Taylor SE. Neural sensitivity to social rejection is associated with inflammatory responses to social stress. Proc Natl Acad Sci U S A 2010; 107:14817-14822.
33. Carpenter LL, Gawuga CE, Tyrka AR, et al. Association between plasma IL-6 response to acute stress and early-life adversity in healthy adults. Neuropsychopharmacology 2010; 35:2617-2623.
34. Fredericks CA, Drabant EM, Edge MD, et al. Healthy young women with serotonin transporter SS polymorphism show a proinflammatory bias under resting and stress conditions. Brain Behav Immun 2010; 24:350-357.
35. Su S, Zhao J, Bremner JD, et al. Serotonin transporter gene, depressive symptoms, and interleukin-6. Circ Cardiovasc Genet 2009; 2:614-620.
36. Baune BT, Dannlowski U, Domschke K, et al. The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression. Biol Psychiatry 2010; 67:543-549.
37. Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry 2011; 16:751-762.
38. Park KM, Bowers WJ. Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cell Signal 2010; 22:977-983.
39. Dean B, Tawadros N, Scarr E, Gibbons AS. Regionally-specific changes in levels of tumour necrosis factor in the dorsolateral prefrontal cortex obtained postmortem from subjects with major depressive disorder. J Affect Disord 2010; 120:245-248.
40. Raison CL, Borisov AS, Majer M, et al. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry 2009; 65:296-303.
41. Gold SM, Kruger S, Ziegler KJ, et al. Endocrine and immune substrates of depressive symptoms and fatigue in multiple sclerosis patients with comorbid major depression. J Neurol Neurosurg Psychiatry 2011; 82:814-818.
42. Kojima M, Kojima T, Suzuki S, et al. Depression, inflammation, and pain in patients with rheumatoid arthritis. Arthritis Rheum 2009; 61:1018-1024.
43. Looper K, Mustafa S, Zelkowitz P, et al. History of depressive episodes as a risk factor for illness severity in early inflammatory arthritis. J Psychosom Res 2011; 71:28-31.
44. Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26:643-652. (Pubitemid 34260983)
45. Bull SJ, Huezo-Diaz P, Binder EB, et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry 2009; 14:1095-1104.
46. Dantzer R, O'Connor JC, Freund GG, et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9:46-56. (Pubitemid 350295688)
47. Reichenberg A, Yirmiya R, Schuld A, et al. Cytokine-associated emotional and cognitive disturbances in humans. ArchGen Psychiatry 2001; 58:445-452. (Pubitemid 32411324)
48. Reichenberg A, Kraus T, Haack M, et al. Endotoxin-induced changes in food consumption in healthy volunteers are associated with TNF-alpha and IL-6 secretion. Psychoneuroendocrinology 2002; 27:945-956. (Pubitemid 35279765)
49. Pitychoutis PM, Nakamura K, Tsonis PA, Papadopoulou-Daifoti Z. Neurochemical and behavioral alterations in an inflammatory model of depression: sex differences exposed. Neuroscience 2009; 159:1216-1232.
50. Harrison NA, Brydon L, Walker C, et al. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry 2009; 66:407-414.
51. Muller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 2007; 12:988-1000. (Pubitemid 350006207)
52. Oxenkrug GF. Tryptophan kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later. Isr J Psychiatry Relat Sci 2010; 47:56-63.
53. Sublette ME, Galfalvy HC, Fuchs D, et al. Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain Behav Immun 2011; 25:1272-1278.
54. Khairova RA, Machado-Vieira R, Du J, Manji HK. A potential role for proinflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol 2009; 12:561-578.
55. Wichers MC, Koek GH, Robaeys G, et al. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005; 10:538-544. (Pubitemid 40897037)
56. Raison CL, Dantzer R, Kelley KW, et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 2010; 15:393-403.
57. Akhondzadeh S, Jafari S, Raisi F, et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 2009; 26:607-611.
58. Nery FG, Monkul ES, Hatch JP, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 2008; 23:87-94. (Pubitemid 351359580)
59. Mendlewicz J, Kriwin P, Oswald P, et al. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int Clin Psychopharmacol 2006; 21:227-231. (Pubitemid 43740300)
60. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367:29-35. (Pubitemid 43038667)
61. Lu DY, Tsao YY, Leung YM, Su KP. Docosahexaenoic acid suppresses neuroinflammatory responses and induces heme oxygenase-1 expression in BV-2 microglia: implications of antidepressant effects for omega-3 fatty acids. Neuropsychopharmacology 2010; 35:2238-2248.
62. Benicky J, Sanchez-Lemus E, Honda M, et al. Angiotensin II AT(1) receptor blockade ameliorates brain inflammation. Neuropsychopharmacology 2011; 36:857-870.
63. Luheshi NM, Rothwell NJ, Brough D. Dual functionality of interleukin-1 family cytokines: implications for antiinterleukin-1 therapy. Br J Pharmacol 2009; 157:1318-1329.
64. Warner-Schmidt JL, Vanover KE, Chen EY, et al. From the cover: antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci U S A 2011; 108:9262-9267.
65. Snyder SH. Serotonin, cytokines, p11, and depression. Proc Natl Acad Sci U S A 2011; 108:8923-8924.
66. Wager-Smith K, Markou A. Depression: a repair response to stress-induced neuronal microdamage that can grade into a chronic neuroinflammatory condition? Neurosci Biobehav Rev 2011; 35:742-764.
67. Sanchez-Villegas A, Delgado-Rodriguez M, Alonso A, et al. Association of the Mediterranean dietary pattern with the incidence of depression: the Seguimiento Universidad de Navarra/University of Navarra follow-up (SUN) cohort. Arch Gen Psychiatry 2009; 66:1090-1098.
68. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010; 67:220-229.
69. Wolkowitz OM, Mellon SH, Epel ES, et al. Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress- preliminary findings. PLoS One 2011; 6:e17837.
70. Kopf M, Bachmann MF, Marsland BJ. Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov 2010; 9:703-718.
71. Li M, Soczynska JK, Kennedy SH. Inflammatory biomarkers in depression: an opportunity for novel therapeutic interventions. Curr Psychiatry Rep 2011. [Epub ahead of print]